Is Matrixyl 3000 the same peptide?

No. Its listed active peptides differ from palmitoyl pentapeptide-4 in original Matrixyl.

Does a 3% blend mean 3% pure peptide?

No. A supplied blend contains carriers; its use level does not directly state the pure-peptide concentration.

Does the evidence guarantee a result by a fixed week?

No. Small trials report outcomes for specific formulations and populations, not universal timelines or individual guarantees.

Palmitoyl Pentapeptide-4: Matrixyl Identity & Skin Evidence

Palmitoyl Pentapeptide-4

Also known as: Pal-KTTKS, Original Matrixyl

Palmitoyl pentapeptide-4 is a topical cosmetic peptide studied in specific moisturizer formulations. Original Matrixyl contains this ingredient; Matrixyl 3000 is a different peptide blend, so its identity and evidence should be evaluated separately.

Identity: Peptide Versus Branded Blend

Croda’s original Matrixyl ingredient list includes palmitoyl pentapeptide-4 with carriers. Matrixyl 3000 instead lists palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7. These manufacturer ingredient lists establish composition, not independent comparative efficacy. A percentage of a supplied blend is also different from a percentage of pure peptide.

Mechanism: What Was Actually Tested?

Katayama et al. (1993) found that the unmodified KTTKS sequence stimulated extracellular-matrix production in cell systems. That is a mechanistic precursor, not proof that every finished palmitoylated cream penetrates equally or produces the same effect. The exact ingredient and formulation remain important.

Human Topical Evidence

Palmitoyl Pentapeptide-4: Human Topical Evidence — selected studies and evidence summaries
Research context	Existing findings, population and limits
2005 moisturizer comparison	Robinson et al. (2005) studied 93 white women aged 35–55 in a 12-week randomized, double-blind, split-face comparison: moisturizer with 3 ppm pal-KTTKS versus the same moisturizer without it. Fine-line/wrinkle measures improved and the tested preparation was well tolerated.
2023 formulation trial	A 2023 randomized trial involved 21 Indonesian women across peptide-cream and placebo groups for eight weeks. It reported preliminary improvements favoring palmitoyl pentapeptide-4, while calling for larger and longer studies. These small formulation-specific studies do not establish superiority to every alternative.

Potential Benefits and Limits

The clinical signal concerns visible fine lines in a studied moisturizer, not general reversal of biological aging or equivalence to injections. It should not be transferred automatically to Matrixyl 3000, oral collagen or a product with a different formula.

Application and Concentration

Follow the finished product’s directions. The 3 ppm research formula is not a universal 0.1–3% pure-peptide recommendation; raw-material blends and active-peptide concentrations are different quantities. The supplier’s ingredient blend is not a home-mixing prescription, and higher percentages alone do not establish greater benefit.

Safety and Tolerability

Tolerability in the 12-week study does not establish lifelong safety for every skin type and formulation. The small 2023 study likewise cannot rule out uncommon reactions. These sources do not establish that every retinoid combination is synergistic or that topical cosmetic effects match injected treatments.

Sources and Review Scope

Editorial source check: October 26, 2026. Sources: Croda original Matrixyl composition, Matrixyl 3000 composition, cell study, 2005 clinical study and 2023 trial. Manufacturer statements are attributed and are not treated as independent clinical proof. Publication checks used indexed abstracts; journal full texts were not reviewed unless specifically stated. This is editorial source review, not clinician signoff or approval of related legacy guides.

Frequently Asked Questions About Palmitoyl Pentapeptide-4